Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD

Bone Marrow Transplantation

Volumn 24, Issue 11, 1999, Pages 1185-1189

  Bertz, H ^a   Afting, M ^a   Kreisel, W ^a   Duffner, U ^a   Greinwald, R ^b   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Dr Falk Pharma GmbH   (Germany)

Author keywords

Acute intestinal GVHD; Budesonide; Endoscopy; Topical corticoid therapy

Indexed keywords

BUDENOFALK; BUDESONIDE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; ENTEROPATHY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 0033376582     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702055     Document Type: Article

References (24)

1. Sullivan KM. Graft-vs-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Cambridge, MA, 1994, pp 339-362.
2. Baehr PH, Levine DS, Bouvier ME, Hockenbery DM et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation 1995; 60: 1231-1238.
3. McDonald GB, Bouvier ME, Hockenbery DM et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease. Gastroenterology 1998; 115: 28-35.
4. Thomson ABR, Sadowski D, Jenkins R, Wild G. Budesonide in the management of patients with Crohn's disease. Can J Gastroenterol 1997; 11: 255-260.
5. Fleig WE. Topische Steroide bei chronisch-entzündlichen Darmerkrankungen. Internist 1997; 38: 1154-1159.
6. Möllmann HW, Hochhaus G, Tromm A et al. Pharamakokinetics and pharmacodynamics of budesonide pH-modified release capsules. In: Möllmann HW, May B (eds), Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. Kluwer Academic Publishers: Dordrecht, 1996, pp 107-120.
7. Edsbäcker S, Wollmer P, Lindberg C et al. Pharmacokinetics and gastrointestinal transit of budenoside controlled ileal release (CIR) capsules. Gastroenterology 1993; 104 (4, Suppl.): A695.
8. Edsbäcker S, Jönsson S, Lindberg C et al. Metabolic pathways of the topically glucocorticoid budesonide in man. Drug Metab Dis 1983; 6: 590-596.
9. Brogdan RN, McTavish D, Barnes PJ et al. Budesonide. An updated review of its pharmacological properties and therapeutic effects in asthma and rhinitis. Drugs 1992; 44: 375-407.
10. Danielson A. Treatment of distal ulcerative colitis with non-systemic corticosteroid enemas. Scand J Gastroenterol 1996; 31: 945-953.
11. Hellers G, Cortot A, Jewell D et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999; 116: 294-300.
12. Lofberg R, Danielsson A, Suhr O et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110: 1713-1718.
13. Rutgeerts P, Löfberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. New Engl J Med 1994; 331: 842-845.
14. Greenberg GR, Feagan BG, Martin F et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110: 45-51.
15. Campieri M, Ferguson A, Doe W et al and the Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997; 41: 209-214.
16. Bertz H, Potthoff K, Mertelsmann R, Finke J. Busulfan/ cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169-1173.
17. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-vs-host disease in human recipients of marrow from HLA-matched siblings donors. Transplantation 1974; 18: 295-304.
18. Snover DC. Graft versus host disease of the gastrointestinal tract. Am J Surg Pathol 1990; 14 (Suppl. 1): 101-108.
19. Lerner KG, Kao GF, Storb R et al. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 1974; 6: 367-371.
20. Kreisel W, Herbst EW, Schwind B et al. Endoscopic diagnosis of graft-versus host disease. Eur J Gastroenterol Hepatol 1994; 8: 723-729.
21. Caesar I, Gross V, Roth M et al. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release Budesonide. Hepatogastroenterology 1997; 44: 445-451.
22. Barth J, Tromm A. Möllmann A et al. Systemic effects of orally administered Budesonide: comparison of a single dose versus divided dose regimen. IV International Symposium about Chronic Inflammatory Bowel Disease 1993. Abstr. 6.
23. Löfberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996; 39: 82-86.
24. Gross V, Andus T, Caesar I et al. Oral pH-modified release budesonide vs 6-methylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 905-909.